Rezultati pretraživanja
  1. 30. ruj 2019.

    Finally Consensus Molecular Subtypes of are out OA. Now let's always include (also) the consensus in our publications. As reviewers, always demand if not included. Transparent and reproducible biological grouping of ahead.  

    27 proslijeđenih tweetova 65 korisnika označava da im se sviđa
  2. 24. sij

    Clinically bad, scientifically intriguing news. Is IO similar to chemo in ? (Neoadj >> Adj)

    5 proslijeđenih tweetova 19 korisnika označava da im se sviđa
  3. 31. lis 2019.

    Great paper by (), and GU colleagues just out in . Result of a and SUO conference to harmonize eligibility criteria and radiographic disease assessments in clinical trials of adjuvant therapy for .

    1 reply 17 proslijeđenih tweetova 47 korisnika označava da im se sviđa
    Prikaži ovu nit
    Prikaži ovu nit
  4. 2. velj

    Nothing beats the with a view

    7 korisnika označava da im se sviđa
  5. 2. lip 2019.

    Another successful Scottish bladder cancer training day at 🏴󠁧󠁢󠁳󠁣󠁴󠁿 - thanks for organising

    8 korisnika označava da im se sviđa
  6. 4. lis 2019.

    Nice audience at the presentation of data on Sustained Intravesical Release Gemcitabine, and very fruitful discussion on the details of upcoming phase III trial

    1 reply 7 proslijeđenih tweetova 20 korisnika označava da im se sviđa
  7. 20. stu 2019.

    Neoadjuvant chemo is guideline recommended for patients with . However, some will not respond. reviews data to predict response:

    13 proslijeđenih tweetova 31 korisnik označava da mu se sviđa
  8. 12. ožu 2019.

    Our take on magnitude of survival benefit associated with definitive vs. non-definitive (palliative) care @DavidDan_Nguyen @SeanFletcher_

    Many patients are reluctant to opt for definitive therapy muscle-invasive due to effects on morbidity and quality of life, but new study shows that definitive therapy is associated with a sizable survival benefit.
    5 proslijeđenih tweetova 11 korisnika označava da im se sviđa
  9. 15. velj 2019.

    , the star fellow of is presenting his work w/ Androgens receptor activity is lower in patients who had received neoadjuvant Cis-based chemo – mjesto: Westfield San Francisco Centre

    1 reply 5 proslijeđenih tweetova 19 korisnika označava da im se sviđa
  10. 15. ruj 2019.

    New standard of care for us Great work

    giving a fantastic talk about hypo-fractionated RT for localized . From a meta-analysis of 2 RCT, is 55 Gy / 20 Fns the new standard of care ?
    3 proslijeđena tweeta 22 korisnika označavaju da im se sviđa
  11. 16. ožu 2019.

    High quality plenary session about conducted by and Take home message: kills, we should try to preserve as much as possible.

    10 proslijeđenih tweetova 19 korisnika označava da im se sviđa
  12. 3. lip 2019.

    S1314 Phase II biomarker study: COXEN score (from NCI-60 in vitro gene expression correlated w/human dataset) in pooled analysis of arms predictive of pCR and downstaging for neoadj for cis/gem (but not ddmvac), further validation underway

    6 proslijeđenih tweetova 7 korisnika označava da im se sviđa
  13. 29. lis 2019.

    Neoadjuvant therapy for in phase 3 trials of chemo+IO for cis-eligible (NCT03661320,NCT03732677,NCT03924856) and IO (NCT03924895) or IO+IO (2018-002676-40) for cis-ineligible pts: collaboration critical

    WATCH: Dr. Sonpavde on Neoadjuvant Immunotherapy in Bladder Cancer
    6 proslijeđenih tweetova 12 korisnika označava da im se sviđa
  14. 20. svi 2019.

    Kick-off TMD Meeting - Il carcinoma vescicale infiltrante : cosa sta cambiando Starting with the pathologist up to date on

    3 proslijeđena tweeta 7 korisnika označava da im se sviđa
  15. 28. ožu 2019.

    The accuracy of CT in determining extravesical tumour extension in varies from 55% to 92% and increases with more advanced disease

    The accuracy of CT in determining extravesical tumour extension in varies from 55% to 92% and increases with more advanced disease
    9 proslijeđenih tweetova 21 korisnik označava da mu se sviđa
  16. 24. tra 2019.
    Odgovor korisniku/ci

    I absolutely agree with you, but might be useful to plan treatment in , of course having done a TURBT. T2 is the subgroup with less benefit from NAC, so if you can rule out T3+ with MRI you could go to cystectomy upfront if you don’t use NAC in T2...

    4 korisnika označavaju da im se sviđa
  17. 29. tra 2019.

    Great multisciplinary panel on trimodality treatment for at ! Thank you for the kind invitation.

    11 korisnika označava da im se sviđa
  18. 7. stu 2019.

    Thankful to participate in S1600 - being exposed to the PG-SGA nutritional evaluation in this study has led to incorporating this evaluation outside of the trial which is a boon to all of our patients. ⁦⁩ ⁦⁩

    1 proslijeđeni tweet 3 korisnika označavaju da im se sviđa
  19. 9. pro 2019.

    Excited to open Neoadjuvant trial of dd Gem-Cis in with bladder sparing option for pts with select genetic alterations led by

    10 proslijeđenih tweetova 39 korisnika označava da im se sviđa
  20. 11. pro 2019.

    Good old clinical pathology outperforms molecular subtypes in multiple patient cohorts and classifications in predicting patient outcomes & chemotherapy response

    36 proslijeđenih tweetova 74 korisnika označavaju da im se sviđa

Nema rezultata.

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.